Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Lymphoproliferative disorder? 225 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 225 reports of Lymphoproliferative disorder have been filed in association with INFLIXIMAB (Renflexis). This represents 0.2% of all adverse event reports for INFLIXIMAB.

225
Reports of Lymphoproliferative disorder with INFLIXIMAB
0.2%
of all INFLIXIMAB reports
21
Deaths
54
Hospitalizations

How Dangerous Is Lymphoproliferative disorder From INFLIXIMAB?

Of the 225 reports, 21 (9.3%) resulted in death, 54 (24.0%) required hospitalization, and 6 (2.7%) were considered life-threatening.

Is Lymphoproliferative disorder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 225 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Lymphoproliferative disorder?

METHOTREXATE (1,392) PREDNISOLONE (178) PREDNISONE (141) TACROLIMUS (139) MYCOPHENOLATE MOFETIL (138) CYCLOPHOSPHAMIDE (136) AZATHIOPRINE (120) ADALIMUMAB (98) CYCLOSPORINE (98) RITUXIMAB (96)

Which INFLIXIMAB Alternatives Have Lower Lymphoproliferative disorder Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Lymphoproliferative disorder Reports All Drugs Causing Lymphoproliferative disorder INFLIXIMAB Demographics